Aileron Therapeutics' Phase 1b trial shows LTI-03 improved biomarkers and reduced SPD levels, indicating the potential to ...

Idiopathic pulmonary fibrosis (IPF) is characterized by a progressive decline in lung function, worsening quality of life, and high mortality. However, the rate and pattern of progression of IPF ...

(RTTNews) - Aileron Therapeutics, Inc. (ALRN), Wednesday announced positive topline data from the cohort 2 of Phase 1b study evaluating LTI-03 in patients with idiopathic pulmonary fibrosis (IPF).

Idiopathic pulmonary fibrosis (an update ... Huang S, Doyle TJ, Hammer MM, et al. Rheumatoid arthritis-related lung disease detected on clinical chest computed tomography imaging: prevalence ...

is a progressive fibrotic lung disease of unknown cause. It remains incurable and has a poor prognosis for many patients, with a median survival of 3-5 years from diagnosis. For more information on ...

The conditions commonly considered as ILDs include various disorders such as idiopathic pulmonary fibrosis (IPF), connective tissue ... and ILDs (e.g., Rheumatoid arthritis, Scleroderma, Sjogren ...

The UAB ILD Center offers clinical trial enrollment for patients with idiopathic pulmonary fibrosis and other forms of diffuse parenchymal lung disease as part of a multidisciplinary and integrated ...

Because these conditions cause aberrant lung function, morbidity and mortality due to lung injury and fibrosis are not uncommon. Both environmental and genetic factors are believed to contribute ...

Agomab Therapeutics NV (‘Agomab’) today announced a $89 million (€82.1 million) Series D financing round, with participation from new investors Sanofi ...

Often regarded as the most common form of ILD, idiopathic pulmonary fibrosis (IPF ... Underlying conditions: Some sarcoidosis ...

The UAB ILD Center offers clinical trial enrollment for patients with idiopathic pulmonary fibrosis and other forms of diffuse parenchymal lung disease as part of a multidisciplinary and integrated ...